MIR22HG and breast cancer: To identify the downstream targets of MIR22HG and miR-629-5p, we analyzed the breast cancer data from The Cancer Genome Atlas (TCGA) database and found that LATS2 expression was positively correlated with MIR22HG expression [12] (Fig. 6a).